FDA blocks much-anticipated BioMarin hemophilia gene therapy

BioMarin Pharmaceutical shares plunged by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news